Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor mus...
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 131
- Registration Number
- NCT01880619
- Locations
- 🇪🇬
Urology and Nephrology Center, Mansoura, Egypt
Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 181
- Registration Number
- NCT01741454
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 545
- Registration Number
- NCT01736033
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju, Chungbuk, Korea, Republic of
🇰🇷Eulji General Hospital, Seoul, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Gyeoggi, Korea, Republic of
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 689
- Registration Number
- NCT01726270
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States
Bioequivalence - Duodart Against Avodart & Omnic
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT01657851
- Locations
- 🇷🇺
GSK Investigational Site, Reutov, Moscow Region, Russian Federation
Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 90
- Registration Number
- NCT01568918
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Albert Einstein Healthcare Network
- Registration Number
- NCT01560091
- Locations
- 🇺🇸
Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1
- Registration Number
- NCT01534351
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01489696
- Locations
- 🇬🇧
Covance CRU Ltd, Leeds, United Kingdom
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Timothy Boone, MD, PhD
- Target Recruit Count
- 10
- Registration Number
- NCT01457573
- Locations
- 🇺🇸
The Methodist Hospital System, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.